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ISSNantiretroviral treatment (ART) interruption on
neurocognition and quality of life (QoL) are important for managing unplanned
interruptions and planned interruptions in HIV cure research.
Design: Children previously randomized to continuous (continuous ART, n¼41) vs.
planned treatment interruption (PTI, n¼47) in the Pediatric European Network
for Treatment of AIDS (PENTA) 11 study were enrolled. At study end, PTI children
resumed ART. At 1 and 2 years following study end, children were assessed by the coding,
symbol search and digit span subtests of Wechsler Intelligence Scale for Children
(6–16 years old) or Wechsler Adult Intelligence Scale (17 years old) and by Pediatrics
QoL questionnaires for physical and psychological QoL. Transformed scaled scores for
neurocognition and mean standardized scores for QoL were compared between arms by
t-test and Mann–Whitney U test, respectively. Scores indicating clinical concern were
compared (<7 for neurocognition and <70 for QoL tests).
Results: Characteristics were similar between arms with a median age of 12.6 years,
CD4þ of 830 cells/ml and HIV RNA of 1.7 log10copies/ml. The median cumulative ART
exposure was 9.6 in continuous ART vs. 7.7 years in PTI (P¼0.02). PTI children had a
median of 12 months off ART and had resumed ART for 25.2 months at time of first
assessment. Neurocognitive scores were similar between arms for all tests. Physical and
psychological QoL scores were no different. About 40% had low neurocognitive and
QoL scores indicating clinical concern.
Conclusion: No differences in information processing speed, sustained attention, short-
term memory and QoL functioning were observed between children previously
randomized to continuous ART vs. PTI in the PENTA 11 trial.
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Severe forms of HIV-associated brain insult or HIV
encephalopathy have fortunately become less common
since the widespread use of antiretroviral therapy (ART).
However, milder but static forms of neurocognitive
impairment (NCI) afflict up to half of children living with
HIV [1–3], and may compromise their successful
transition into adulthood. Advanced HIV disease and
unsuppressed HIV viremia are predictors of poor
neurocognition as well as quality of life (QoL) [4–6].
Therefore, ART interruption may negatively impact
these factors.
Here we capitalize on the unique opportunity to assess
neurocognition and QoL in children who were
randomized to continuous ART vs. CD4þ-guided
planned treatment interruption (PTI) in the Pediatric
European Network for Treatment of AIDS (PENTA)
11 trial [7]. At the end of the trial, PTI children were
advised to reinitiate ART and after 2 years of ART
resumption, similar clinical, immunological, and virolo-
gical outcomes were observed between arms [8].
However, neurocognition and QoL have not yet been
compared. As the Strategies for Management of
Antiretroviral Therapy study in adults showed excessive
risks for adverse outcomes with PTI even after ARTwas
reinitiated [9], we conducted this substudy to compare
neurocognition and QoL at 1 and 2 years following the
end of the PENTA 11 study. Although PTI is not a
recommended treatment strategy, this study is relevant to
the treatment of HIV-infected children because
unplanned ART interruption is not infrequent, particu-
larly in adolescents [10], and treatment interruption may
be a critical component of future HIV cure research [11].
Understanding the effects of ART interruption on
neurocognition and QoL could inform monitoring and
intervention of these children.Methods
This is a substudy of the PENTA 11 trial
(ISRCTN36694210) in which virally suppressed HIV-
infected children were randomized to either 72 weeks of
continuous ART vs. PTI as previously described [7]. At
trial end in May 2008, ART was reinitiated in PTI
children and routine HIV care data were collected in both
arms for 5 years as part of the long-term cohort study [8].
In addition, children were offered enrollment in this
substudy with annual neurocognitive and QoL assess-
ments; here we include data from years 1 and 2. The
neurocognitive measures were three subscales (coding,
symbol search, and digit span) from either the Wechsler
Intelligence Scale for Children (WISC IV for those aged
6 to <17 years old) or the Wechsler Adult Intelligence
Scale (WAIS IV for those aged 17 years old). Scaled Copyright © 2016 Wolters Kluwer Hscores rather than raw scores are reported as these are
corrected for age and are comparable for the WISC and
WAIS scales. The coding and symbol search subscales
assess speed of information processing and sustained
attention, whereas digit span assesses short-term memory.
These tests were selected because they evaluate cognitive
domains that have been reported as most vulnerable to the
effects of HIV (short-term memory, attention, and
processing speed) and they depend less on verbal or
language comprehension, therefore, maximizing data
fidelity across ethnic and language contexts. Additionally,
participating sites had experience administering these
tests.
Children and carers were also separately asked to
complete Pediatrics Quality of Life (PedsQL) question-
naires [12]. These scales contain 23 items about physical,
emotional, social, and school functions. There are age
appropriate versions from 5 to more than 18 years old. All
items were rated on a 5-point rating scale and scores were
then standardized on 100-point scale in which higher
scores reflected better QoL. Carers gave their consent and
consent/assent was obtained from children according to
local practices. The study was approved by Ethics
Committees for all participating sites.
Data Analysis
The neurocognitive raw scores were transformed into
normative scaled scores; means on each scale were
computed and the number of children with a scaled score
below seven was obtained. This cutoff represents scores
significantly below the test mean compared with others of
the same age. On the PedsQL, overall mean scores for
physical and psychosocial functions were computed, as
were scores of 70 or less on any scale. This cutoff has been
used to indicate clinical concern [13].
Differences between mean continuous ART and PTI
arm scores were tested for each neurocognitive test and
QoL assessment score, using an independent samples
t-test and Mann–Whitney U test, respectively. This
outcome was analyzed using exact logistic regression to
test for differences between the two arms, with the
analysis adjusted for sex, Centers for Disease Control
and Prevention (CDC) class C status, nadir CD4%, and
continent. An identical sensitivity analysis was
also performed by excluding children with HIV
encephalopathy.Results
Of 101 children (51 continuous ART and 50 PTI) from
the PENTA 11 trial who were eligible for inclusion, 88
children from seven countries participated in this
substudy (41 continuous ART and 47 PTI). Table 1
shows the characteristics of the children at time of theirealth, Inc. All rights reserved.
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Table 1. Characteristics of children at time of their first neurocognitive and quality of life assessment.
Total (n¼88)a
Children in CT arm (n¼41)
(73% of all children in CT arm)
Children in PTI arm (n¼47)
(84% of all children in PTI arm) P value
Median (IQR) age 12.6 (9.6–15.2) 12.9 (10.1–15.3) 12.6 (9.5–14.4) 0.77
Women, n (%) 50 (57%) 25 (61%) 25 (53%) 0.46
Ethnicity, n (%)
White 33 (38%) 14 (34%) 19 (40%) 0.72
Black 22 (25%) 9 (22%) 13 (28%)
Asian/Thai 22 (25%) 12 (29%) 10 (21%)
Other 11 (13%) 6 (15%) 5 (12%)
CDC clinical stage C 25 (28%) 16 (39%) 9 (19%) 0.04
Weight for age Z score 0.3 (1.2 0.8) 0.3 (1.5 1.1) 0.3 (1.2 0.4) 0.75
Height for age Z score 0.5 (1.6 0.5) 0.4 (1.7 0.5) 0.5 (1.4 0.5) 0.74
Median (IQR) nadir CD4% 17 (12–24) 18 (12–28) 16 (11–22) 0.08
Median (IQR) CD4% 36 (32–40) 38 (34–40) 34 (29–40) 0.03
Median (IQR) CD4þ cell count
(cells/ml)
830 (693–1058) 866 (750–1065) 814 (630–981) 0.27
Median (IQR) HIV RNA
(log10copies/ml)
1.7 (1.6–1.7) 1.7 (1.6–1.7) 1.7 (1.7–2.0) 0.08
Current ART regimen, n (%)
Efavirenz 26 (30%) 11 (27%) 15 (32%) 0.60
Nevirapine 24 (27%) 13 (32%) 11 (23%)
Boosted PI 6 (7%) 3 (7%) 3 (6%)
Unboosted PI 21 (24%) 10 (24%) 11 (23%)
PI and NNRTI 5 (6%) 3 (7%) 2 (4%)
Off ART 4 (5%) 0 (0%) 4 (9%)
Other 2 (2%) 1 (2%) 1 (2%)
Median (IQR) cumulative ART
exposure (years)
8.3 (6.0–11.0) 9.6 (7.1–12.4) 7.7 (5.2–10.5) 0.02
Median (IQR) cumulative time of
ART interruption (months)
– Not applicable 12.0 (7.0–18.2)
Median (IQR) time since ART
interruption (months)
– Not applicable 25.2 (18.9–31.2)
These characteristics were collected one year after the main PENTA 11 trial ended and children had their first neurocognitive and quality of life
assessments. ART, antiretroviral therapy; CT, continuous antiretroviral treatment; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; PTI, partial treatment interruption.
aParticipating sites in: France, Ireland, Italy, Poland, Spain, Switzerland, and United Kingdom.first assessment 1 year after the main trial ended. Both the
continuous ARTand PTI groups were similar in age, sex,
ethnicity, and HIV-related factors except that there
tended to be more CDC grade C illnesses in the
continuous ART arm (P¼ 0.05) and CD4% was slightly
lower in PTI arm although very similar at 2 years [8]. Two
continuous ART children had HIV encephalopathy but
none in the PTI arm. The cumulative time on ARTwas
longer in the continuous ARTarm. The PTI children had
about 1 year of ART interruption and had been back on
ART for about 2 years at the time of their first
neurocognitive and QoL assessment.
Table 2 shows the neurocognitive and PedsQL outcomes.
The mean scaled scores and the proportion with low
scaled scores for all three neurocognitive tasks were not
significantly different between arms for both years 1 and
2. In year 1, 38% had scaled score below seven on at least
one test, with low scores observed in 18% for symbol
search, 20% for coding, and 20% for digit span. In year 2,
the scaled scores and proportion of children with low
scores were similar between arms. There were no
significant changes between year 1 and 2 for all
neurocognitive subscales except for a trend toward fewer
children having low scores in year 2 for symbol search and
digit span. Copyright © 2016 Wolters KluweThe mean scores on the physical or psychological scales
of the PedsQL were similar for those in the continuous
ART and PT arms for the carer reports for years 1 and 2;
physical but not psychological scores for the child were
lower in the PTI arm in year 2 only (Table 2). The
proportions of children with low scores, that is, less than
70, on either the physical or the psychological scale were
not different between arms. Combining the two arms
found the percentage of all children scoring less than 70 in
year 1 to be 14% for the physical scale and 28% for the
psychosocial scale; results were similar in year 2 (Table 2).
Carers reported a higher level of concern in most areas
than the children. The neurocognitive and QoL out-
comes did not change when children with HIV
encephalopathy were excluded.Discussion
Although continuous ART is the standard of care,
adherence to ART is not easy and clinicians are faced
with managing unplanned ART interruptions in
children and teenagers [10,14]. The randomized PENTA
11 study offers a unique opportunity to evaluate if ART
interruption guided by CD4RR had adverse neurocognitiver Health, Inc. All rights reserved.
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Table 2. Neurocognitive and quality of life outcomes.
Neurocognitive outcomes
Total (n¼88) Children in CT arm (n¼41) Children in PTI arm (n¼47) P value
Neurocognitive tasks Mean scaled score (SD) Mean scaled score (SD)
Symbol search
Year 1 9.2 (3.0) 8.9 (2.9) 9.6 (3.0) 0.28
Year 2 9.6 (2.8) 9.8 (3.1) 9.4 (2.5) 0.48
Coding
Year 1 8.8 (3.1) 8.4 (3.1) 9.2 (3.2) 0.22
Year 2 8.7 (2.8) 8.7 (3.0) 8.8 (2.7) 0.86
Digit span
Year 1 9.5 (3.2) 9.1 (3.2) 9.9 (3.3) 0.29
Year 2 9.5 (3.0) 9.2 (2.8) 9.8 (3.2) 0.40
Neurocognitive tasks N with mean scaled score <7 (%) N with mean scaled score <7 (%)
Symbol search
Year 1 15 (18) 10 (25) 5 (12) 0.14
Year 2 10 (13) 5 (14) 5 (13) >0.99
Coding
Year 1 17 (20) 9 (23) 8 (18) 0.59
Year 2 17 (22) 7 (18) 10 (26) 0.60
Digit span
Year 1 17 (20) 10 (24) 7 (16) 0.28
Year 2 11 (14) 7 (18) 4 (10) 0.25
Quality-of-life outcomes
Children in CT arm (n¼41)
(73% of all children in CT arm)
Children in PTI arm (n¼47)
(84% of all children in PTI arm) P value
PEDsQL – child report scales Mean score (SD) Mean score (SD)
Physical functioning
Year 1 82.8 (14.7) 86.1 (10.6) 80.0 (17.1) 0.15
Year 2 86.0 (13.9) 89.6 (11.3) 82.5 (15.4) 0.04
Psychosocial functioning
Year 1 74.9 (15.7) 75.3 (16.3) 74.5 (15.4) 0.77
Year 2 78.2 (12.4) 79.5 (10.8) 77.0 (13.8) 0.44
PEDsQL – carer report scales
Physical functioning
Year 1 77.9 (20.1) 79.3 (20.4) 76.6 (20.1) 0.40
Year 2 80.6 (21.1) 81.2 (21.8) 80.1 (20.7) 0.51
Psychosocial functioning
Year 1 72.0 (17.0) 70.6 (17.7) 73.3 (16.3) 0.46
Year 2 73.4 (15.4) 73.8 (14.0) 73.0 (16.7) 0.95
PEDsQL – child report scales N with mean score <70 (%) N with mean score <70 (%)
Physical functioning
Year 1 11 (14) 2 (5) 9 (21) 0.17
Year 2 11 (14) 3 (8) 8 (21) 0.48
Psychosocial functioning
Year 1 22 (28) 10 (27) 12 (28) >0.99
Year 2 17 (22) 7 (19) 10 (26) 0.66
PEDsQL – carer report scales
Physical functioning
Year 1 24 (29) 11 (28) 13 (31) >0.99
Year 2 18 (25) 8 (24) 10 (26) >0.99
Psychosocial functioning
Year 1 30 (37) 17 (43) 13 (31) 0.29
Year 2 25 (35) 12 (35) 13 (34) >0.99
CT, continuous antiretroviral treatment; PTI, partial treatment interruptionand QoL consequences. Here we demonstrated that
children who had interrupted ART for about a year and
subsequently resumed ART for an average of 2 years
performed similarly on information processing speed,
sustained attention and short-term memory compared
with those who had not interrupted therapy. Almost 40% Copyright © 2016 Wolters Kluwer Hhad scores below those of healthy children, illustrating the
chronic stable NCI that continues to be prevalent in
children living with HIV [1,3]. QoL scores were also
similar between randomized arms but approximately
one-third of children had scores in the range that indicate
clinical concern.ealth, Inc. All rights reserved.
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macrophages and astrocytes, and indirectly, by triggering
inflammatory responses – both processes could be more
pronounced in the immature brain [15,16]. HIV proteins
such as gp120, Tat, Nef, and Vpr can also be neurotoxic by
causing neuronal cell death when released from HIV-
infected cells, possibly leading to functional impairment
[17]. Consequently, the magnitude and duration of HIV
viremia predicts NCI [18] leading to our concern of
adverse consequences in the interrupted arm of this study.
No studies have investigated the effects of ART interrup-
tion on neurocognition and QoL but inferences could be
drawn from those that evaluate timing of ART on these
factors. The Pediatric Randomized to Early versus
Deferred Initiation in Cambodia and Thailand study
randomized children who were about 6 years old to
initiating ARTat CD4þ 15–24% vs. deferring until CD4þ
less than 15% and did not find differences in intelligent
quotients and psychomotor performance nor QoL scores
after 3 years [19,20]. However, the Children with HIV
Early Antiretroviral Therapy study observed poorer
neurocognitive outcomes in infants who were randomized
to defer ART until CD4þ 25% vs. those who initiated
before 3 months of age [21]. These data suggest that brain
insult from HIV likely occurs early during infancy [22,23];
therefore, delayed ART or ART interruption might not
have an apparent effect on brain functioning in older
children. A consistent finding across studies remains that a
significant proportion of children with HIV perform
poorer on neurocognitive and QoL tests [4–6]. The
impaired information processing, sustained attention and
short-term memory observed in our patients could
potentially have long-term adverse consequences on
school and social functioning [24]. This is further
supported by the low scores on these subscales of the
QoL in our children (data not shown).
Our study is limited by the lack of assessment at baseline
or during ART interruption; therefore, any prior
differences between arms cannot be accounted for.
Because a comprehensive battery of assessments was not
performed, subtle differences between arms could have
been missed. Importantly, psychosocial and environmen-
tal data relevant to neurocognition and QoL were not
collected. The duration of follow-up was relatively short,
and NCI may become apparent later when children are
older and required to engage in complex tasks. More of
the continuous ART arm children were in the CDC C
advanced HIV stage at the beginning of the main trial
(64 vs. 32% in PTI), and fewer (73%) participated in the
neurocognitive substudy compared with 84% of PTI
children. This may have contributed to the favorable
outcome observed in the PTI arm. However, both arms
experienced no deaths or CDC C events during the
entire follow-up duration.
The HIV field was reinvigorated with the news of HIV
remission in the Mississippi baby [25], which sadly turned Copyright © 2016 Wolters Kluweout not to be sustained [26]. In HIV cure research,
intensively monitored antiretroviral pause (iMAP) is being
employed as the ultimate test for a cure. iMAP is defined as
a pause in ART that is accompanied by frequent
monitoring for viral load rebound followed by a prompt
resumption of treatment if rebound occurs [27]. Several
studies involving administration of therapeutic vaccines
with and without iMAP are being planned [28,29]. Our
study provides reassuring information that no short-term
neurocognitive and QoL effects from treatment interrup-
tion were observed. However, as these cure studies progress
and include early treated children who may have preserved
cognitive function, the effects of treatment interuption on
neurocognition should be closely observed.
Finally, millions of children with HIV around the world
are entering adolescence. Future research should focus on
understanding their development of executive function
including decision-making, planning, and self-regulation
by taking into account the psychosocial and environ-
mental contexts [30,31]. It will be important to leverage
opportunities to study neurocognitive functioning in the
context of treatment trials including pediatric cure trials
to optimize performance and successful transition of
youth with HIV into the work force.Acknowledgements
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l’Archet, Nice: F. Monpoux, S. Mellul (L), I. Caranta
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